

Myotonic disorders: A review article

Chris Hahn¹, Mohammad Kian Salajegheh¹

Received: 25 Aug 2015

Accepted: 08 Nov 2015

¹ Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA

Keywords

Myotonia, Myotonic Dystrophy, Myotonia Congenita, Paralysis Periodica Paramyotonia, Hyperkalemic Periodic Paralysis

Abstract

The myotonic disorders are a heterogeneous group of genetically determined diseases that are unified by the presence of myotonia, which is defined as failure of muscle relaxation after activation. The presentation of these disorders can range from asymptomatic electrical myotonia, as seen in some forms of myotonia congenita (MC), to severe disability with muscle weakness, cardiac conduction defects, and other systemic features as in myotonic dystrophy type I (DM1). In this review, we describe the clinical features and pathophysiology of the different myotonic disorders, their laboratory and electrophysiologic findings and briefly review the currently available treatments.

Introduction

The myotonic disorders are a group of rare, genetically heterogeneous syndromes presenting with clinical and/or electrical myotonia. Clinical myotonia is characterized by the failure of muscle relaxation after activation.¹ Electrical myotonia is the spontaneous discharge of muscle fibers that waxes and wanes in both amplitude and frequency on electromyography (EMG). Myotonia is thought to be due to increased excitability of muscle fibers, leading to discharge of repetitive action potentials in response to stimulation.² Electrical myotonia can also be seen with certain drugs (cholesterol lowering agents, cyclosporine, and colchicine, among others), in inflammatory myopathies, Pompe disease,

hypothyroidism, myotubular myopathy, and chronic denervation (usually as brief runs).¹

Clinical myotonia manifests with painless muscle stiffness, although some forms can be associated with pain.^{2,3} The typical location of stiffness varies depending on the underlying disorder but commonly seen in the eyelids, mouth, hands, and proximal legs.³⁻⁶ Common triggers include cold, stress and exercise, and symptoms can worsen during pregnancy and menstruation.³ Most demonstrate a "warm-up" phenomenon, where myotonia improves with repeated action.^{3,5,6} In contrast, paradoxical myotonia or paramyotonia worsens with repeated use. Some forms of myotonia are also associated with diffuse muscle hypertrophy.⁷

Myotonia can be brought out by asking the patient to repeatedly grip and relax their hand or open and close their eyes. Alternatively, direct percussion of a muscle can achieve the same effect; including tapping the thenar eminence, forearm extensors, or even tongue.⁸

Typically, myotonias are classified as either dystrophic or non-dystrophic. The former are characterized by fixed muscle weakness, systemic features, and dystrophic changes on muscle biopsy. Fixed weakness and dystrophic changes are less common, but can be seen in the non-dystrophic myotonias (NDM), and myopathic changes may be noted on muscle biopsy.⁹ Recent evidence suggests structural muscles changes on magnetic resonance imaging and ultrasound imaging of some patients.^{7,10} The clinical features of familial myotonic disorders are mentioned in table 1.

Myotonic dystrophy (DM1)

Table 1. Clinical features of familial myotonic disorders

Conditions	Inheritance	Gene	Myotonia	Episodic weakness	Fixed weakness	Major trigger	Other features
DM							
DM type 1	AD	DMPK	M	Absent	Distal limbs, face	None	Frontal balding, temporal wasting, cataracts, systemic disease
Myotonic dystrophy type 2 (PROMM)	AD	CNBP (ZNF9)	M	Absent*	Proximal limbs	None	Disabling and atypical pain, cataracts, milder systemic disease
NDM							
MC							
AD (Thomsen)	AD	CLCN1	M	Absent	Rare	Rest	Generalized muscle hypertrophy
AR (Becker)	AR	CLCN1	M	Absent*	Proximal LE	Rest	Muscle hypertrophy in LE
PMC	AD	SCN4A	P	Present in some	Proximal LE	Cold, exercise	Most sensitive to cold
Potassium-sensitive periodic paralysis	AD	SCN4A	P, M or absent	Present	Proximal LE	K+, rest after exercise	Potassium levels may be high***
PAM							
Myotonia fluctuans	AD	SCN4A	M**	Absent	Absent	K+, exercise	Have good days and bad days
Myotonia permanens	AD	SCN4A	M**	Absent	Absent	K+, exercise	Continuous muscle stiffness
Acetazolamide-responsive myotonia	AD	SCN4A	M**	Absent	Absent	K+, exercise	Respond to therapy with acetazolamide

*PROMM patients may initially have intermittent or transient weakness; recessive MC patients may have transient weakness after severe bouts of stiffness, **May have eyelid paramyotonia, ***Potassium levels may be normal during attack normokalemic periodic paralysis (normoKPP).

AD: Autosomal dominant; AR: Autosomal recessive; K+: Potassium, LE: Lower extremities; M: Myotonia; P: Paramyotonia; PROMM: Proximal myotonic myopathy; DM: Dystrophic myotonias

autosomal dominant fashion and classified into type I (DM1) and type II (DM2), also known as proximal myotonic myopathy (PROMM). Both are caused by expansion of DNA tandem repeats, resulting in a toxic gain of function of the resulting mutant RNA and sequestration of RNA-binding proteins.¹¹ DM1 results from expansion of CTG repeats in the DM protein kinase (DMPK) gene^{12,13} whereas DM2 is caused by expansion of CCTG repeats in the ZNF9 gene.^{14,15}

DM1

DM1 has an estimated prevalence of 3-15 per 100000^{16,17} with higher prevalence reported in Sweden, the Basque area of Spain, and the Saguenay region of Quebec, Canada, where it is up to 20 times higher.^{16,18} To our knowledge, disease prevalence has not been reported in Iran, but the incidence of excess DMPK CTG repeats in healthy Iranian controls is reported to be similar to Western Europe and Japan.¹⁹

DM1 can present at any age and often occurs earlier in successive generations, showing marked anticipation.²⁰ Larger repeat expansions are associated with earlier onset and more severe forms of the disease in most cases.²⁰⁻²⁵ The most severe form, congenital DM, presents at birth with generalized hypotonia, severe weakness, facial diplegia (tent shaped mouth), intellectual disability, hypoventilation, gastrointestinal (GI) dysmotility, and early death.^{17,23} Interestingly, myotonia is usually absent in infancy and muscle strength can improve with time if the infant survives.

Classically, DM1 presents in the second to fourth decade with prominent facial weakness, including ptosis, neck extension/flexion weakness, and distal weakness with a predilection for finger flexors/extensors and foot dorsiflexors.²⁰ Muscle atrophy occurs in line with the progression of weakness and myotonia is common (particularly in the hands).^{17,22,25} Temporal muscle atrophy, ptosis and frontal balding result in a characteristic myotonic facies, and dysphagia and dysarthria are often prominent. Weakness tends to progress slowly over time with more than 95.0% of patients remaining ambulatory after a mean disease duration of 16-19 years.^{20,26}

Systemic features include cardiac disease, especially conduction defects and possibly cardiomyopathy.²⁷ Cataracts are seen early (before 50 years in most) with bilateral iridescent (Christmas tree) or posterior cortical lens opacities being highly specific for DM1.²⁸ GI symptoms have been attributed to smooth muscle dysfunction and include reflux, abdominal pain, bloating, constipation, and diarrhea.²⁹ Endocrinopathies, in the form of insulin resistance and hypogonadism may also occur.³⁰

Excessive daytime sleepiness, independent of obstructive sleep apnea,³¹ is common. Patients may have mild cognitive impairment and often have an avoidant personality with apathy toward their disease.^{32,33} More recently, associations with mild peripheral neuropathy³⁴ and increased risk of cancer have been suggested.³⁵ Mild forms, limited to myotonia, frontal balding and early cataracts with normal strength and lifespan also occur, usually in patients with lower number of repeats.^{20,22}

DM2

The prevalence of DM2 or PROMM is unclear but reported as even higher than DM1 in some populations in Finland and the Czech Republic.^{36,37} Unlike DM1, there is no clear relationship between the number of repeats and disease severity³⁶ and congenital forms have not been reported. Most patients present in middle age with a mild phenotype of proximal weakness, myalgias, and early cataracts. Weakness characteristically involves neck flexors, elbow extensors, thumb/deep finger flexors, hip flexors and hip extensors. Facial weakness is less common.³⁸ Marked muscle atrophy is uncommon, and calf hypertrophy can be seen in some.³⁷ Muscle pain is present in 56-76%^{38,39} of patients and occasionally leads to a misdiagnosis of fibromyalgia.^{40,41} Clinical myotonia is often absent, and patients can occasionally present with asymptomatic hyperCKemia.^{37,38,42}

Systemic features are similar to DM1 but milder.^{35,38,43,44} Cognitive function is mostly normal although mild changes have been reported.⁴⁵⁻⁴⁷ Dysphagia is common but typically mild.^{48,49} In addition, there are reports of higher incidence of autoimmune disease compared to controls and DM1.⁵⁰

Diagnosis and treatment of DMs

The evaluation of patients suspected to have myotonic dystrophy should include a thorough family history and physical examination, including testing of strength and myotonia. Definitive diagnosis is through genetic testing, commercially available for both DM1 and DM2. CK levels can be normal to moderately elevated,^{38,39} and other laboratory features include mild hypogammaglobulinemia and non-specific liver enzyme abnormalities.³⁷ Nerve conduction studies are usually normal but can show mild length dependent axonal polyneuropathy. EMG shows myotonic discharges in all patients with DM1 and 90-100% of patients with DM2.^{38,51,52} Myopathic units, fibrillation potentials, and positive sharp waves can also be seen but are sometimes obscured by prominent myotonic discharges. Muscle biopsy in DM1 shows atrophy of type I fibers, increased

internalized nuclei, ring fibers, sarcoplasmic masses, small angulated fibers, and atrophic fibers with pyknotic clumps.^{16,17} DM2 may show similar features but milder and with atrophy of type II fibers, in contrast.

Treatment of the myotonic dystrophies is symptomatic and should include screening for cardiac arrhythmias, glucose intolerance, obstructive sleep apnea, and cataracts. Limited evidence exists for drug treatment of myotonia with antiepileptic and antiarrhythmia agents.⁵³ A recent randomized controlled trial demonstrated efficacy of mexiletine in patients with DM1;⁵⁴ however, concerns have been raised regarding its long-term safety in DM1 patients due to the potential of cardiac arrhythmias.⁵⁵ We use it with caution in patients with DM1 and in consultation with cardiology. It may be started at 150 mg twice daily and slowly increased to a maximum of 300 mg 3 times daily. An electrocardiogram should be performed at baseline and periodically.

Excessive daytime somnolence is sometimes treated with stimulants, although evidence for efficacy is mixed.⁵⁶⁻⁵⁹ GI complaints can occasionally be due to small intestine bacterial overgrowth and may respond to antibiotic therapy,⁶⁰ and prokinetic agents have been used to treat gastroparesis.⁶¹

NDM

These are a group of rare disorders caused by mutations in genes coding for sodium (SCN4A) or chloride (CLCN1) channels. Their prevalence is estimated at ~1/100000 with higher rates (7-9/100000) in Northern Finland and Norway.⁶²⁻⁶⁵ CLCN1 mutations are the most common form of NDM (0.52/100000) followed by paramyotonia congenita (PMC) (0.17/100000).⁶⁵

The muscle chloride channel was previously thought to be important in stabilizing the resting membrane potential, with mutations leading to a lower threshold for muscle membrane firing.⁶⁶ More recent studies bring this into question.⁶⁷ Sodium channel mutations lead to poor inactivation of the channel, which results in repetitive discharges, with mild depolarization, or weakness, with severe depolarization.^{68,69}

Myotonia congenita (MC)

MC is a chloride channelopathy, typically divided into dominant (Thomsen disease) and recessive (Becker disease) forms. Over 150 mutations in the CLCN1 gene have been reported,⁷⁰ with the recessive form of the disease classically presenting earlier in life with a more severe phenotype, although mild or late presentations have been reported.^{71,72}

Thomsen disease was initially described by

Thomsen himself in 1876, through a detailed description of his own disability and that of his family members.⁷³ It typically presents in the first decade with stiffness in legs more than arms, hands, and face.^{3,6,72} Penetrance is incomplete, and disease severity can vary widely in family members.⁷⁴ Classically, stiffness is worse after rest, and patients often complain of leg stiffness that improves with walking. Myotonia can also affect muscles of mastication and swallowing. Some patients describe pain associated with their stiffness.^{3,6} Warm-up phenomenon is usually present, and the stiffness can worsen with cold exposure, pregnancy, menses, hypothyroidism, and stress.^{3,6,17,75,76} Examination demonstrates generalized muscular hypertrophy, action myotonia more pronounced in the hands than eyelids,^{3,6} and percussion myotonia. Thomsen disease is not associated with systemic features, and patients have normal lifespans.

Becker disease usually presents between the ages of 4 and 12 years, although onset in adulthood is also seen.^{72,73} Symptoms are similar to Thomsen disease, but myotonia tends to be more severe in the lower limbs and proximal muscles, and men tend to be more severely affected than women.⁷² Transient weakness, lasting seconds to minutes, is sometimes seen after sustained bouts of myotonia and patients often have difficulty moving if startled suddenly.^{6,73} Patients may develop mild fixed distal weakness and a "dystrophic" variant with severe atrophy and weakness, contractures and myopathic changes on muscle biopsy.⁷⁷ Similar to Thomsen disease, no systemic features are seen, and lifespan is normal.

Laboratory investigations are usually normal in both dominant and recessive MC although mild elevations in CK can be seen.⁷³ EMG shows widespread myotonic discharges and myopathic motor units can be seen in weak muscles if not obscured by myotonia. Given the commercial availability of genetic testing, muscle biopsy is rarely done and shows non-specific changes or mildly increased variability in fiber size and increased number of internalized nuclei.⁷³

PMC

PMC is an autosomal dominant condition caused by mutations in the SNC4A gene. It is highly penetrant and typically presents in the first decade with stiffness that is most pronounced in the face and hands. In contrast to other forms of myotonia, the patients have paramyotonia.^{3,6} It commonly worsens with cold and patients can develop severe weakness with the prolonged exposure that can take hours to improve despite rewarming.^{17,78,79} Patients may complain of hand stiffness while shoveling snow or in the frozen

food section of the supermarket. Parents will occasionally report that affected infants are unable to open their eyes after a crying spell, presumably due to the eyelids being "exercised" while crying.

Myotonia can worsen with pregnancy, menstruation, ingestion of potassium-rich food, and anesthetics.^{3,78} Muscle hypertrophy is less common than in MC, and some patients develop progressive weakness with time.⁷⁸ This disorder is allelic with potassium-sensitive periodic paralysis, and some patients demonstrate features of both disorders with episodes of generalized weakness.^{9,79,80} Lifespan is unaffected and systemic involvement is not a feature of PMC.⁸¹

Examination of affected patients shows eyelid and grip paramyotonia in most patients,⁷⁸ but percussion myotonia is not prominent. Immersing a limb in cold water can worsen myotonia and result in weakness. Laboratory investigations show mild elevations in CK, and potassium levels can be high or normal during episodes of weakness.^{79,82} EMG shows diffuse myotonic discharges, which can worsen with cooling of the affected limb, as well as eventual electrically silent contractures with progressive cooling.⁸³ Genetic testing is commercially available, and muscle biopsy demonstrates non-specific myopathic changes with occasional vacuoles.^{9,82}

Potassium aggravated myotonia (PAM)

These are a group of autosomal dominant NDMs characterized by sensitivity to potassium ingestion without episodic weakness. They are caused by mutations in SCN4A and include myotonia fluctuans, myotonia permanens, and acetazolimide responsive myotonia. CK levels can be normal or mildly elevated, and EMG shows diffuse myotonic discharges and fibrillation potentials. Commercial genetic testing is available, and changes on muscle biopsy are not well-described.⁸⁴⁻⁸⁷

Myotonia fluctuans typically presents in the first to the second decade of life, with myotonia that fluctuates from day-to-day. Patients can be asymptomatic 1 day and have severe myotonia affecting the limbs, extraocular muscles, muscles of mastication, and swallowing on other days. Myotonia is accompanied by "warm-up" phenomenon and increases with potassium ingestion and with a short delay (usually minutes) after exercise. Patients do not develop fixed weakness, and there is no increase in myotonia with exposure to cold.^{84,85,88} Eyelid paramyotonia is frequently seen on examination while grip myotonia is less common.

Myotonia permanens is characterized by constant, generalized myotonia that can affect respiration and even lead to hypoxia and respiratory acidosis.^{68,86} It has been reported with neonatal episodic laryngospasm,⁸⁹

and to worsen with potassium ingestion, fever, pregnancy and after exercise,^{86,87} without associated weakness or exacerbation with cooling.

Acetazolimide responsive myotonia presents as painful muscle stiffness in childhood that can involve proximal limbs, muscles of mastication, and extraocular muscles. It worsens with potassium and fasting but may improve with carbohydrate ingestion. Examination shows variable muscle hypertrophy, easily elicitable action and percussion myotonia and paradoxical myotonia in the eyelids.^{90,91}

Potassium-sensitive periodic paralysis

This disorder, also called hyperkalemic periodic paralysis (HyperPP), is associated with autosomal dominant mutations in SCN4A. It can present as a pure periodic paralysis syndrome or as periodic paralysis with clinical/electrical myotonia or paramyotonia.¹⁷ Myotonia is usually mild, often involving the eyelids, hands, and tongue. The attacks of weakness can occur at any time and are commonly triggered by rest the following exercise, fasting, ingestion of food high in potassium or stress.⁹² Some patients may develop progressive myopathy.⁹³

Other sodium channel myotonias

Severe neonatal episodic laryngospasm is a recently described entity consisting of recurrent laryngospasm which results in apnea and apparent life-threatening events in neonates. This has been associated with multiple mutations in SCN4A.^{89,94,95} It remains unclear if this is a de novo disorder or represents a neonatal presentation of NDM.

Diagnosis and treatment of NDM

Clinical examination and electrodiagnostic studies are helpful in narrowing down the differential before ordering commercially available genetic tests. Pronounced sensitivity to cold is most suggestive of PMC, although mild cold intolerance is present in other forms. Myotonia tends to be more prominent in the legs in MC, leading to difficulty standing up quickly, while more prominent in the arms and face in PAM. Eye closure myotonia, as well as grip and eye closure paramyotonia, are more common with SCN4A mutations and warm-up phenomenon with MC.^{3,6} Patients with recessive MC,⁹⁶ PMC, and HyperPP are more likely to report episodes of transient paresis.

The degree of myotonic discharges does not seem to differ greatly between MC and sternocleidomastoid on EMG, but may be less in DM2.^{3,97}

The use of the short exercise test, in particular with cooling, has proven useful in differentiating various forms of myotonia.^{98,99} The long exercise test can also

be helpful, but typically used for diagnosing periodic paralysis.⁹⁷

Treatment of NDM includes the avoidance of triggers and, if necessary, symptomatic treatment of myotonia. PMC patients should be counseled to avoid cold exposure, and HyperPP, PMC or PAM patients to avoid foods rich in potassium (banana, papaya, mango, beans, and dried fruits). Mexiletine use for treatment of myotonia has been supported by a recent randomized control trial.¹⁰⁰ The most common side effect is GI distress¹⁰¹ that may improve if taken with food. Serious side effects include ventricular arrhythmias and patients should have regular EKG monitoring. Other medications, mostly affecting sodium channels, have shown varying success, including carbamazepine, phenytoin, procainamide, and flecainide.⁸⁷ Acetazolamide may work well in acetazolamide-responsive myotonia⁹¹ but rarely reported to cause paralysis in PMC.^{102,103}

Conclusion

The myotonic disorders are a heterogeneous group of diseases that result in clinical and/or electrical myotonia. The resulting severity can range from asymptomatic electrical myotonia, as in some cases of dominant MC, to severe disability as in advanced DM1 or myotonia permanens. Correct diagnosis is important for genetic counseling, treatment and proper screening for systemic features. Currently, treatment remains symptomatic, but research in therapies that target the genetic or molecular pathophysiology of these diseases is ongoing.¹⁰⁴⁻¹⁰

Conflict of Interests

The authors declare no conflict of interest in this study.

How to cite this article: Hahn C, Salajegheh MK. Myotonic disorders: A review article. *Iran J Neurol* 2016; 15(1): 46-53.

References

1. Preston DC, Shapiro BE. Electromyography and neuromuscular disorders. 3rd ed. Philadelphia, PA: Elsevier Health Sciences; 2012.
2. Hudson AJ, Ebers GC, Bulman DE. The skeletal muscle sodium and chloride channel diseases. *Brain* 1995; 118(Pt 2): 547-63.
3. Trivedi JR, Bundy B, Statland J, Salajegheh M, Rayan DR, Venance SL, et al. Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. *Brain* 2013; 136(Pt 7): 2189-200.
4. Machuca-Tzili L, Brook D, Hilton-Jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. *Muscle Nerve* 2005; 32(1): 1-18.
5. Matthews E, Fialho D, Tan SV, Venance SL, Cannon SC, Sternberg D, et al. The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. *Brain* 2010; 133(Pt 1): 9-22.
6. Trip J, Drost G, Ginjaar HB, Nieman FH, van der Kooij AJ, de Visser M, et al. Redefining the clinical phenotypes of non-dystrophic myotonic syndromes. *J Neurol Neurosurg Psychiatry* 2009; 80(6): 647-52.
7. Trip J, Pillen S, Faber CG, van Engelen BG, Zwarts MJ, Drost G. Muscle ultrasound measurements and functional muscle parameters in non-dystrophic myotonias suggest structural muscle changes. *Neuromuscul Disord* 2009; 19(7): 462-7.
8. Campbell WW. DeJong's the neurologic examination. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.
9. Miller TM, Dias da Silva MR, Miller HA, Kwiecinski H, Mendell JR, Tawil R, et al. Correlating phenotype and genotype in the periodic paralyses. *Neurology* 2004; 63(9): 1647-55.
10. Morrow JM, Matthews E, Raja Rayan DL, Fischmann A, Sinclair CD, Reilly MM, et al. Muscle MRI reveals distinct abnormalities in genetically proven non-dystrophic myotonias. *Neuromuscul Disord* 2013; 23(8): 637-46.
11. Mankodi A, Teng-Umuay P, Krym M, Henderson D, Swanson M, Thornton CA. Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. *Ann Neurol* 2003; 54(6): 760-8.
12. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. *Science* 1992; 255(5049): 1253-5.
13. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. *Cell* 1992; 68(4): 799-808.
14. Bachinski LL, Udd B, Meola G, Sansone V, Bassez G, Eymard B, et al. Confirmation of the type 2 myotonic dystrophy (CCTG)_n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. *Am J Hum Genet* 2003; 73(4): 835-48.
15. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. *Science* 2001; 293(5531): 864-7.
16. Harper PS. Myotonic dystrophy. Oxford, UK: Oxford University Press; 2002.
17. Amato A, Russell J. Neuromuscular disorders. New York, NY: McGraw Hill Professional; 2008.
18. Mathieu J, de Braekeleer M, Prevost C. Genealogical reconstruction of myotonic dystrophy in the Saguenay-Lac-Saint-Jean area (Quebec, Canada). *Neurology* 1990; 40(5): 839-42.
19. Shojasaffar B, Moradin N, Kahrizi K, Cobo AM, Najmabadi H. CTG expansion & haplotype analysis in DM1 gene in healthy Iranian population. *Can J Neurol Sci* 2008; 35(2): 216-9.
20. Bouchard JP, Cossette L, Bassez G, Puymirat J. Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases. *J Neurol* 2015; 262(2): 285-93.
21. Antonini G, Giubilei F, Mammarella A, Amicucci P, Fiorelli M, Gragnani F, et al. Natural history of cardiac involvement in myotonic dystrophy: correlation with CTG repeats. *Neurology* 2000; 55(8): 1207-9.
22. Arsenaault ME, Prevost C, Lescault A, Laberge C, Puymirat J, Mathieu J. Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansions. *Neurology* 2006; 66(8): 1248-50.
23. Campbell C, Levin S, Siu VM, Venance S, Jacob P. Congenital myotonic dystrophy: Canadian population-based surveillance study. *J Pediatr* 2013; 163(1): 120-5.
24. Hunter A, Tsilfidis C, Mettler G, Jacob P, Mahadevan M, Surh L, et al. The correlation of age of onset with CTG trinucleotide repeat amplification in myotonic dystrophy. *J Med Genet* 1992; 29(11): 774-9.
25. Khoshbakht R, Soltanzadeh A, Zamani B, Abdi S, Gharagozli K, Kahrizi K, et al. Correlation between distribution of muscle weakness, electrophysiological findings and CTG expansion in myotonic dystrophy. *J Clin Neurosci* 2014; 21(7): 1123-6.
26. Johnson ER, Abresch RT, Carter GT, Kilmer DD, Fowler WM, Sigford BJ, et al. Profiles of neuromuscular diseases. Myotonic dystrophy. *Am J Phys Med Rehabil* 1995; 74(5 Suppl): S104-S116.
27. Lund M, Diaz LJ, Ranthe MF, Petri H, Duno M, Juncker I, et al. Cardiac involvement in myotonic dystrophy: a nationwide cohort study. *Eur Heart J* 2014; 35(32): 2158-64.
28. Ashizawa T, Hejtmanck JF, Liu J,

- Perryman MB, Epstein HF, Koch DD. Diagnostic value of ophthalmologic findings in myotonic dystrophy: comparison with risks calculated by haplotype analysis of closely linked restriction fragment length polymorphisms. *Am J Med Genet* 1992; 42(1): 55-60.
29. Bellini M, Biagi S, Stasi C, Costa F, Mumolo MG, Ricchiuti A, et al. Gastrointestinal manifestations in myotonic muscular dystrophy. *World J Gastroenterol* 2006; 12(12): 1821-8.
30. Peric S, Nisic T, Milicevic M, Basta I, Marjanovic I, Peric M, et al. Hypogonadism and erectile dysfunction in myotonic dystrophy type 1. *Acta Myol* 2013; 32(2): 106-9.
31. van der Meche FG, Bogaard JM, van der Sluys JC, Schimsheimer RJ, Ververs CC, Busch HF. Daytime sleep in myotonic dystrophy is not caused by sleep apnoea. *J Neurol Neurosurg Psychiatry* 1994; 57(5): 626-8.
32. Rubinsztein JS, Rubinsztein DC, Goodburn S, Holland AJ. Apathy and hypersomnia are common features of myotonic dystrophy. *J Neurol Neurosurg Psychiatry* 1998; 64(4): 510-5.
33. Delaporte C. Personality patterns in patients with myotonic dystrophy. *Arch Neurol* 1998; 55(5): 635-40.
34. Hermans MC, Faber CG, Vanhoutte EK, Bakkers M, de Baets MH, de Die-Smulders CE, et al. Peripheral neuropathy in myotonic dystrophy type 1. *J Peripher Nerv Syst* 2011; 16(1): 24-9.
35. Gadalla SM, Lund M, Pfeiffer RM, Gortz S, Mueller CM, Moxley RT, III, et al. Cancer risk among patients with myotonic muscular dystrophy. *JAMA* 2011; 306(22): 2480-6.
36. Suominen T, Bachinski LL, Auvinen S, Hackman P, Baggerly KA, Angelini C, et al. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. *Eur J Hum Genet* 2011; 19(7): 776-82.
37. Udd B, Meola G, Krahe R, Wansink DG, Bassez G, Kress W, et al. Myotonic dystrophy type 2 (DM2) and related disorders report of the 180th ENMC workshop including guidelines on diagnostics and management 3-5 December 2010, Naarden, The Netherlands. *Neuromuscul Disord* 2011; 21(6): 443-50.
38. Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. *Neurology* 2003; 60(4): 657-64.
39. Suokas KI, Haanpaa M, Kautiainen H, Udd B, Hietaharju AJ. Pain in patients with myotonic dystrophy type 2: a postal survey in Finland. *Muscle Nerve* 2012; 45(1): 70-4.
40. Auvinen S, Suominen T, Hannonen P, Bachinski LL, Krahe R, Udd B. Myotonic dystrophy type 2 found in two of sixty-three persons diagnosed as having fibromyalgia. *Arthritis Rheum* 2008; 58(11): 3627-31.
41. Hilbert JE, Ashizawa T, Day JW, Luebke EA, Martens WB, McDermott MP, et al. Diagnostic odyssey of patients with myotonic dystrophy. *J Neurol* 2013; 260(10): 2497-504.
42. Merlini L, Sabatelli P, Columbaro M, Bonifazi E, Pisani V, Massa R, et al. Hyper-CK-emia as the sole manifestation of myotonic dystrophy type 2. *Muscle Nerve* 2005; 31(6): 764-7.
43. Win AK, Perattur PG, Pulido JS, Pulido CM, Lindor NM. Increased cancer risks in myotonic dystrophy. *Mayo Clin Proc* 2012; 87(2): 130-5.
44. Romigi A, Albanese M, Placidi F, Izzi F, Liguori C, Marciani MG, et al. Sleep disorders in myotonic dystrophy type 2: a controlled polysomnographic study and self-reported questionnaires. *Eur J Neurol* 2014; 21(6): 929-34.
45. Peric S, Mandic-Stojmenovic G, Stefanova E, Savic-Pavicevic D, Pesovic J, Ilic V, et al. Frontostriatal dysexecutive syndrome: a core cognitive feature of myotonic dystrophy type 2. *J Neurol* 2015; 262(1): 142-8.
46. Meola G, Sansone V, Perani D, Scarone S, Cappa S, Dragoni C, et al. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). *Neuromuscul Disord* 2003; 13(10): 813-21.
47. Meola G, Sansone V, Perani D, Colleluori A, Cappa S, Cotelli M, et al. Reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy. *Neurology* 1999; 53(5): 1042-50.
48. Tieleman AA, Knuijt S, van Vliet J, de Swart BJ, Ensink R, van Engelen BG. Dysphagia is present but mild in myotonic dystrophy type 2. *Neuromuscul Disord* 2009; 19(3): 196-8.
49. Tieleman AA, van Vliet J, Jansen JB, van der Kooij AJ, Borm GF, van Engelen BG. Gastrointestinal involvement is frequent in Myotonic Dystrophy type 2. *Neuromuscul Disord* 2008; 18(8): 646-9.
50. Tieleman AA, den Broeder AA, van de Logt AE, van Engelen BG. Strong association between myotonic dystrophy type 2 and autoimmune diseases. *J Neurol Neurosurg Psychiatry* 2009; 80(11): 1293-5.
51. Young NP, Daube JR, Sorenson EJ, Milone M. Absent, unrecognized, and minimal myotonic discharges in myotonic dystrophy type 2. *Muscle Nerve* 2010; 41(6): 758-62.
52. Bassez G, Attarian S, Laforet P, Azulay JP, Rouche A, Ferrer X, et al. [Proximal myotonic myopathy (PROMM): clinical and histology study]. *Rev Neurol (Paris)* 2001; 157(2): 209-18.
53. Udd B, Meola G, Krahe R, Thornton C, Ranum LP, Bassez G, et al. 140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. *Neuromuscul Disord* 2006; 16(6): 403-13.
54. Logigian EL, Martens WB, Moxley RT, McDermott MP, Dilek N, Wiegner AW, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. *Neurology* 2010; 74(18): 1441-8.
55. Groh WJ. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. *Neurology* 2011; 76(4): 409.
56. Puymirat J, Bouchard JP, Mathieu J. Efficacy and tolerability of a 20-mg dose of methylphenidate for the treatment of daytime sleepiness in adult patients with myotonic dystrophy type 1: a 2-center, randomized, double-blind, placebo-controlled, 3-week crossover trial. *Clin Ther* 2012; 34(5): 1103-11.
57. Annane D, Moore DH, Barnes PR, Miller RG. Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy. *Cochrane Database Syst Rev* 2006; (3): CD003218.
58. Orlikowski D, Chevret S, Quera-Salva MA, Laforet P, Lofaso F, Verschuere A, et al. Modafinil for the treatment of hypersomnia associated with myotonic muscular dystrophy in adults: a multicenter, prospective, randomized, double-blind, placebo-controlled, 4-week trial. *Clin Ther* 2009; 31(8): 1765-73.
59. Wintzen AR, Lammers GJ, van Dijk JG. Does modafinil enhance activity of patients with myotonic dystrophy? a double-blind placebo-controlled crossover study. *J Neurol* 2007; 254(1): 26-8.
60. Tarnopolsky MA, Pearce E, Matteliano A, James C, Armstrong D. Bacterial overgrowth syndrome in myotonic muscular dystrophy is potentially treatable. *Muscle Nerve* 2010; 42(6): 853-5.
61. Horowitz M, Maddox A, Maddern GJ, Wishart J, Collins PJ, Shearman DJ. Gastric and esophageal emptying in dystrophia myotonica. Effect of metoclopramide. *Gastroenterology* 1987; 92(3): 570-7.
62. Baumann P, Myllyla VV, Leisti J. Myotonia congenita in northern Finland: an epidemiological and genetic study. *J Med Genet* 1998; 35(4): 293-6.
63. Sun C, Tranebjaerg L, Torbergesen T, Holmgren G, van Ghelue M. Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern Scandinavia. *Eur J Hum Genet* 2001; 9(12): 903-9.
64. Emery AE. Population frequencies of inherited neuromuscular diseases--a world survey. *Neuromuscul Disord* 1991; 1(1): 19-29.
65. Horga A, Raja Rayan DL, Matthews E, Sud R, Fialho D, Durran SC, et al. Prevalence study of genetically defined skeletal muscle channelopathies in England. *Neurology* 2013; 80(16): 1472-5.
66. Adrian RH, Bryant SH. On the repetitive discharge in myotonic muscle fibres. *J Physiol* 1974; 240(2): 505-15.
67. Tan SV, Z'Graggen WJ, Boerio D, Rayan DR, Norwood F, Ruddy D, et al. Chloride channels in myotonia congenita assessed by velocity recovery cycles. *Muscle Nerve* 2014; 49(6): 845-57.
68. Lerche H, Heine R, Pika U, George AL, Mitrovic N, Browatzki M, et al. Human sodium channel myotonia: slowed channel inactivation due to substitutions for a glycine within the III-IV linker. *J Physiol* 1993; 470: 13-22.
69. Lehmann-Horn F, Rudel R, Ricker K, Lorkovic H, Dengler R, Hopf HC. Two cases of adynamia episodica hereditaria: in vitro investigation of muscle cell membrane and contraction parameters. *Muscle Nerve* 1983; 6(2): 113-21.
70. Dunø M, Colding-Jørgensen E. Myotonia congenita. Seattle, WA: University of Washington, Seattle; 2011.
71. Gurgel-Giannetti J, Senkevics AS, Zilbersztajn-Gotlieb D, Yamamoto LU, Muniz VP, Pavanetto RC, et al. Thomsen or Becker myotonia? A novel autosomal

- recessive nonsense mutation in the CLCN1 gene associated with a mild phenotype. *Muscle Nerve* 2012; 45(2): 279-83.
72. Colding-Jorgensen E. Phenotypic variability in myotonia congenita. *Muscle Nerve* 2005; 32(1): 19-34.
 73. Erich Kuhn S, Fiehn W, Seiler D, Schröder JM. The autosomal recessive (Becker) form of myotonia congenita. *Muscle & Nerve* 1979; 2(2): 109-17.
 74. Plassart-Schiess E, Gervais A, Eymard B, Lagueny A, Pouget J, Warter JM, et al. Novel muscle chloride channel (CLCN1) mutations in myotonia congenita with various modes of inheritance including incomplete dominance and penetrance. *Neurology* 1998; 50(4): 1176-9.
 75. Lacomis D, Gonzales JT, Giuliani MJ. Fluctuating clinical myotonia and weakness from Thomsen's disease occurring only during pregnancies. *Clin Neurol Neurosurg* 1999; 101(2): 133-6.
 76. Passeri E, Sansone VA, Verdelli C, Mendola M, Corbetta S. Asymptomatic myotonia congenita unmasked by severe hypothyroidism. *Neuromuscul Disord* 2014; 24(4): 365-7.
 77. Nagamitsu S, Matsuura T, Khajavi M, Armstrong R, Gooch C, Harati Y, et al. A "dystrophic" variant of autosomal recessive myotonia congenita caused by novel mutations in the CLCN1 gene. *Neurology* 2000; 55(11): 1697-703.
 78. Matthews E, Tan SV, Fialho D, Sweeney MG, Sud R, Haworth A, et al. What causes paramyotonia in the United Kingdom? Common and new SCN4A mutations revealed. *Neurology* 2008; 70(1): 50-3.
 79. Haass A, Ricker K, Rudel R, Lehmann-Horn F, Bohlen R, Dengler R, et al. Clinical study of paramyotonia congenita with and without myotonia in a warm environment. *Muscle Nerve* 1981; 4(5): 388-95.
 80. Plassart E, Eymard B, Maurs L, Hauw JJ, Lyon-Caen O, Fardeau M, et al. Paramyotonia congenita: genotype to phenotype correlations in two families and report of a new mutation in the sodium channel gene. *J Neurol Sci* 1996; 142(1-2): 126-33.
 81. Pereon Y, Lande G, Demolombe S, Nguyen The Tich S, Sternberg D, Le Marec H, et al. Paramyotonia congenita with an SCN4A mutation affecting cardiac repolarization. *Neurology* 2003; 60(2): 340-2.
 82. Thrush DC, Morris CJ, Salmon MV. Paramyotonia congenita: a clinical, histochemical and pathological study. *Brain* 1972; 95(3): 537-52.
 83. Nielsen VK, Friis ML, Johnsen T. Electromyographic distinction between paramyotonia congenita and myotonia congenita: effect of cold. *Neurology* 1982; 32(8): 827-32.
 84. Ricker K, Lehmann-Horn F, Moxley RT, III. Myotonia fluctuans. *Arch Neurol* 1990; 47(3): 268-72.
 85. Ricker K, Moxley RT, Heine R, Lehmann-Horn F. Myotonia fluctuans. A third type of muscle sodium channel disease. *Arch Neurol* 1994; 51(11): 1095-102.
 86. Colding-Jorgensen E, Duno M, Vissing J. Autosomal dominant monosymptomatic myotonia permanens. *Neurology* 2006; 67(1): 153-5.
 87. Desaphy JF, Modoni A, Lo Monaco M, Camerino DC. Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy. *Eur J Clin Pharmacol* 2013; 69(4): 1037-9.
 88. Lennox G, Purves A, Marsden D. Myotonia fluctuans. *Arch Neurol* 1992; 49(10): 1010-1.
 89. Caietta E, Milh M, Sternberg D, Lepine A, Boulay C, McGonigal A, et al. Diagnosis and outcome of SCN4A-related severe neonatal episodic laryngospasm (SNEL): 2 new cases. *Pediatrics* 2013; 132(3): e784-e787.
 90. Ptacek LJ, Tawil R, Griggs RC, Meola G, McManis P, Barohn RJ, et al. Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita, and hyperkalemic periodic paralysis. *Neurology* 1994; 44(8): 1500-3.
 91. Trudell RG, Kaiser KK, Griggs RC. Acetazolamide-responsive myotonia congenita. *Neurology* 1987; 37(3): 488-91.
 92. Layzer RB, Lovelace RE, Rowland LP. Hyperkalemic periodic paralysis. *Arch Neurol* 1967; 16(5): 455-72.
 93. Bradley WG, Taylor R, Rice DR, Hausmanowa-Petruzewicz I, Adelman LS, Jenkison M, et al. Progressive myopathy in hyperkalemic periodic paralysis. *Arch Neurol* 1990; 47(9): 1013-7.
 94. Singh RR, Tan V, Hanna MG, Robb SA, Clarke A, Jungbluth H. Mutations in SCN4A: A Rare but Treatable Cause of Recurrent Life-Threatening Laryngospasm. *Pediatrics* 2014; 134(5): e1447-e1450.
 95. Lion-Francois L, Mignot C, Vicart S, Manel V, Sternberg D, Landrieu P, et al. Severe neonatal episodic laryngospasm due to de novo SCN4A mutations: a new treatable disorder. *Neurology* 2010; 75(7): 641-5.
 96. Fialho D, Schorge S, Pucovska U, Davies NP, Labrum R, Haworth A, et al. Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions. *Brain* 2007; 130(Pt 12): 3265-74.
 97. Fournier E, Arzel M, Sternberg D, Vicart S, Laforet P, Eymard B, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. *Ann Neurol* 2004; 56(5): 65-1.
 98. Fournier E, Viala K, Gervais H, Sternberg D, Arzel-Hezode M, Laforet P, et al. Cold extends electromyography distinction between ion channel mutations causing myotonia. *Ann Neurol* 2006; 60(3): 356-65.
 99. Tan SV, Matthews E, Barber M, Burge JA, Rajakulendran S, Fialho D, et al. Refined exercise testing can aid DNA-based diagnosis in muscle channelopathies. *Ann Neurol* 2011; 69(2): 328-40.
 100. Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, et al. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. *JAMA* 2012; 308(13): 1357-65.
 101. Trip J, Drost G, van Engelen BG, Faber CG. Drug treatment for myotonia. *Cochrane Database Syst Rev* 2006; (1): CD004762.
 102. Griggs RC, Moxley RT, III, Riggs JE, Engel WK. Effects of acetazolamide on myotonia. *Ann Neurol* 1978; 3(6): 531-7.
 103. Riggs JE, Griggs RC, Moxley RT. Acetazolamide-induced weakness in paramyotonia congenita. *Ann Intern Med* 1977; 86(2): 169-73.
 104. Zhang W, Wang Y, Dong S, Choudhury R, Jin Y, Wang Z. Treatment of type 1 myotonic dystrophy by engineering site-specific RNA endonucleases that target (CUG)(n) repeats. *Mol Ther* 2014; 22(2): 312-20.
 105. Mulders SA, van Engelen BG, Wieringa B, Wansink DG. Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function. *Hum Mol Genet* 2010; 19(R1): R90-R97.
 106. Novak KR, Norman J, Mitchell JR, Pinter MJ, Rich MM. Sodium channel slow inactivation as a therapeutic target for myotonia congenita. *Ann Neurol* 2015; 77(2): 320-32.
 107. Desaphy JF, Carbonara R, Costanza T, Conte CD. Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs. *Exp Neurol* 2014; 255: 96-102.